Drug Trial Radar · NCT07285265
Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Actual
Start
May 27, 2025
Primary completion
Nov 6, 2025
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- Suzhou Abogen Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Abogen Biosciences (Shanghai) Co., Ltd
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of 2 injections (approximately 2 months apart) of three different dose levels of ABO1108 in adults aged 40 years or above.
Conditions
- Varicella-zoster Virus
Interventions
ABO1108Biological
Formulation for injection
PlaceboDrug
0.9% sodium chloride (normal saline) injection
SHINGRIXBiological
• Formulation for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of solicited AEs and ARs after each doseTime frame: up to day 74 (14 days after each dose)
- Incidence of unsolicited AEs and ARs after each doseTime frame: up to day 90 (30 days after each dose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rongshui Miao Autonomous County Center for Disease Control and Prevention
Liuzhou, Rongshui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.